Skip to main content
. 2017 Oct 2;125(10):107001. doi: 10.1289/EHP1612

Figure 2.

Nine plots with confidence intervals showing log base 2 PFAS concentrations, namely, PFNA, PFOA, PFHxS, Me-PFOSA-AcOH, PFOS, and Et-PFOSA-AcOH (y-axis) across the change per year (x-axis) for the following glycemic outcomes: HOMA-IR, HOMA-beta, fasting insulin (micro units per milliliter), fasting glucose in milligrams per deciliter, HbA1c in percentage, fasting proinsulin in picomolar, corrected insulin response, insulinogenic index, adiponectin in micrograms per milliliter.

Adjusted estimated change in glycemic outcomes per year for each doubling in per- and polyfluoroalkyl substances (PFAS) plasma concentrations measured at baseline in the Diabetes Prevention Program. Note: Longitudinal models adjusted for participant sex, race/ethnicity, baseline body mass index (BMI) (continuous), age (categorical), marital status (categorical), education (categorical), smoking history (categorical), time to follow-up in years, and treatment assignment (placebo/lifestyle). Et-PFOSA-AcOH, N-ethyl-perfluorooctane sulfonamido acetic acid; Me-PFOSA-AcOH, N-methyl-perfluorooctane sulfonamido acetic acid; PFHxS, perfluorohexane sulfonic acid; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctanesulfonic acid.